Knight Therapeutics Secures Brazilian Approval for NIKTIMVO® in Rare…

Event summary

Knight Therapeutics received expedited regulatory approval from ANVISA for NIKTIMVO® (axatilimab) to treat chronic graft-versus-host disease (cGVHD) in Brazil.
The approval covers adult and pediatric patients (6+ years, ≥40 kg) who have failed at least two prior systemic therapies.
NIKTIMVO® is a first-in-class CSF-1R-blocking antibody, originally approved in the U.S. for the same indication.
Knight expanded its partnership with Incyte in August 2025 to distribute NIKTIMVO® and other products in Latin America.

The big picture

Knight Therapeutics' approval of NIKTIMVO® in Brazil strengthens its position as a key player in Latin America's rare disease market. The deal reflects a broader trend of pharmaceutical companies leveraging strategic partnerships to expand access to innovative therapies in high-growth emerging markets. With approximately 1,400–1,800 allogeneic transplants annually in Brazil and a 29.5% 2-year cumulative incidence of cGVHD, the approval addresses a significant unmet medical need.

What we're watching

Commercial Execution: Whether Knight can effectively commercialize NIKTIMVO® in Brazil, given the competitive landscape and patient population dynamics.
Clinical Pipeline: The progress of ongoing Phase 2 and Phase 3 trials for axatilimab in combination therapies for cGVHD and other indications.
Regulatory Strategy: The pace at which Knight secures approvals for NIKTIMVO® and other Incyte-partnered products in additional Latin American markets.